| Price | 2,124.00p on 08-04-2026 at 09:48:00 |
|---|---|
| Change | 28.00p 1.34% |
| Buy | 2,125.00p |
| Sell | 2,124.00p |
| Last Trade: | Sell 790.00 at 2,124.401p |
| Day's Volume: | 1,845,352 |
| Last Close: | 2,096.00p |
| Open: | 2,126.00p |
| ISIN: | GB00BN7SWP63 |
| Day's Range | 2,117.00p - 2,142.00p |
| 52wk Range: | 1,268.00p - 2,282.00p |
| Market Capitalisation: | £84.89b |
| VWAP: | 2,128.72535p |
| Shares in Issue: | 4.00b |
Glaxosmithkline (GSK) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Sell* | 790 | 2,124.401p | Ordinary |
10:48:00 - 08-Apr-26 |
| Sell* | 337 | 2,124.00p | Automatic Execution |
10:47:48 - 08-Apr-26 |
| Sell* | 7 | 2,124.00p | SI Trade |
10:47:46 - 08-Apr-26 |
| Buy* | 178 | 2,124.00p | Automatic Execution |
10:47:32 - 08-Apr-26 |
| Unknown* | 0 | 2,123.00p | SI Trade |
10:47:23 - 08-Apr-26 |
| Sell* | 1 | 2,122.155p | Ordinary |
10:47:13 - 08-Apr-26 |
| Buy* | 624 | 2,123.00p | Automatic Execution |
10:47:12 - 08-Apr-26 |
| Buy* | 828 | 2,122.63p | Suspected BUY Trade |
10:47:12 - 08-Apr-26 |
| Buy* | 1 | 2,123.00p | SI Trade |
10:47:05 - 08-Apr-26 |
| Sell* | 42 | 2,122.00p | Ordinary |
10:47:01 - 08-Apr-26 |
Glaxosmithkline (GSK) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 7th Apr 2026 7:00 am | RNS | Transaction in Own Shares |
| 2nd Apr 2026 7:00 am | RNS | Transaction in Own Shares |
| 1st Apr 2026 3:30 pm | RNS | Director/PDMR Shareholding |
| 1st Apr 2026 3:00 pm | RNS | Total Voting Rights |
| 1st Apr 2026 7:00 am | RNS | ViiV completes changes to minority shareholding |
| 1st Apr 2026 7:00 am | RNS | Transaction in Own Shares |
| 31st Mar 2026 7:00 am | RNS | Transaction in Own Shares |
| 30th Mar 2026 7:05 am | RNS | Bepirovirsen accepted for review in China |
| 30th Mar 2026 7:00 am | RNS | Exdensur approved for severe asthma in China |
| 30th Mar 2026 7:00 am | RNS | Transaction in Own Shares |
